Results 101 to 110 of about 582,852 (293)

Phosphate binder is not phosphate binder! Sevelamer may be different! [PDF]

Nephrology Dialysis Transplantation, 2010
H. Schiffl, S. M. Lang
openaire   +1 more source

The multifaceted roles of lysosomes in cancer

Molecular Oncology, EarlyView.
Lysosomes support cancer cell adaptation by integrating macromolecule degradation and nutrient recycling with nutrient sensing, inter‐organelle communication and immune regulation. These interconnected functions can promote tumour growth, stress tolerance and therapy resistance, while also creating context‐dependent vulnerabilities that may be ...
Jia Li, Kevin M. Ryan
wiley   +1 more source

Establishment and validation of a prediction model for mineral and bone disorder in maintenance hemodialysis patients

Zhongguo Linchuang Yixue
ObjectiveTo explore the risk factors for mineral and bone disorder in maintenance hemodialysis patients, and to construct and validate a nomogram prediction model.
Yanling Huang, Jiping Shen, Kai Cao, Ping Xie, Jinyuan Zhao, Rulian Liang   +5 more
doaj   +1 more source

Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study

BMC Nephrology, 2011
Background Lanthanum carbonate (FOSRENOL®) is an effective, well-tolerated phosphate binder. The ability of lanthanum to reduce serum phosphorus levels to ≤5.5 mg/dL in patients with end-stage renal disease (ESRD) was assessed in a clinical practice ...
Matalon Albert, Michelis Michael F, Vemuri Nirupama   +2 more
doaj   +1 more source

USP7 inhibits FOXO1 activity in chronic lymphocytic leukaemia cells enhancing cell survival

Molecular Oncology, EarlyView.
CLL cells rely on BCR‐mediated signalling for survival and proliferation in part through suppression of FOXO1. FOXO1 activity is regulated by a plethora of post‐translational modifications including phosphorylation and ubiquitination. We demonstrated that dual inhibition of BCR signalling and the deubiquitinase USP7 activates FOXO1, modulating its ...
Hassan N.B. Almuhanna, Jodie Hay, Michael W. Moles, Lucy Clarke, Jennifer Cassels, Alison Sefcick, Alison M. McCaig, Heather G. Jørgensen, Alison M. Michie   +8 more
wiley   +1 more source

Research on Rapid Repairing Material for Concrete Structures Undergone Natural Disaster

工程科学与技术, 2010
:In order to determine the optimal proportion of magnesium phosphate cement-based binder (MPB), influences of setting adjusting agent, ratio of phosphate to magnesia, ratio of binder to sand, and addition of fly ash on the setting time and strength ...
Gao Xiaojian, Yang Yingzi, Deng Honhwei, Li Manxi   +3 more
doaj  

Safety and Phosphate‐Binding Capacity of Oxylanthanum Carbonate in Healthy Volunteers

Clinical and Translational Science
Despite the widespread use of currently available serum phosphate management options, elevated serum phosphate is common in patients with end‐stage kidney disease on dialysis.
Pablo E. Pergola, Melanie S. Joy, Armando Garsd, Steve J. Hasal, Atul Khare, Guru Reddy, Pramod Gupta, William F. Finn   +7 more
doaj   +1 more source

Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients. [PDF]

Clin Kidney J, 2023
Egli-Spichtig D, Hamid AK, Arroyo EMP, Ketteler M, Wiecek A, Rosenkranz AR, Pasch A, Lorenz H, Hellmann B, Karus M, Ammer R, Rubio-Aliaga I, Wagner CA.   +12 more
europepmc   +1 more source

Binder Saturation, Layer Thickness, Drying Time and Their Effects on Dimensional Tolerance and Density of Cobalt Chrome - Tricalcium Phosphate Biocomposite [PDF]

, 2020
Traditional metals such as stainless steel, titanium and cobalt chrome are used in biomedical applications (implants, scaffolds, etc.) but suffer from issues such as osseointegration and compatibility with existing bone.
Ruprecht, John
core  

Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas

Molecular Oncology, EarlyView.
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis, Tereza Buchtová, Jirina Bartkova, Marie Lund Bay, Christoffer Lynge Halvorsen, Zuzana Machacova, Zdenek Skrott, Martin Mistrik, Ekaterina Dulina, Miguel Andujar‐Sanchez, Estrid Høgdall, Tine Henrichsen Schnack, Claus Høgdall, Berit Jul Mosgaard, Marie Boennelycke, Jacob Brink Laursen, Allan Jensen, Susanne K. Kjær, Tuula Kallunki, Robert Strauss, Jiri Bartek   +20 more
wiley   +1 more source